[1]Apostu D, Lucaciu O, Berce C, et al. Current methods of preventing aseptic loosening and improving osseointegration of titanium implants in cementless total hip arthroplasty: a review[J]. J Int Med Res, 2017.
[2]Eastwood SE, John A, Jones SA, et al. Osteoclastogenesis-related cytokines and peri-prosthetic osteolysis in revision metal-on-metal total hip replacements[J]. Hip Int, 2015, 25(4): 355-360.
[3]Müller M, Wassilew G, Perka C. Diagnosis and therapy of particle disease in total hip arthroplasty[J]. Z Orthop Unfall, 2015, 153(2): 213-229.
[4]Samujh C, Bhimani S, Smith L, et al. Wear analysis of second-generation highly cross-linked polyethylene in primary total hip arthroplasty[J]. Orthopedics, 2016, 39(6): 1.
[5]Ponzio DY, Austin MS. Metaphyseal bone loss in revision knee arthroplasty [J]. Curr Rev Musculoskelet Med, 2015, 8(4): 361-367.
[6]Qian Y, Zhang XL, Jiang Y, et al. Alendronate stimulates osteoprotegerin expression in fibroblasts from periprosthetic membrane[J]. Hip Int, 2015, 25(6): 581-584.
[7]Chen Y, Lv L, Pi H, et al. Dihydromyricetin protects against liver ischemia/reperfusion induced apoptosisviaactivation of FOXO3a-mediated autophagy[J]. Oncotarget, 2016, 7(47): 76508-76522.
[8]Li X, Liu J, Lin J, et al. Protective effects of dihydromyricetin against OH-induced mesenchymal stem cells damage and mechanistic chemistry[J]. Molecules, 2016, 21(5): 604.
[9]Lei L, Jing W, Lang H, et al. Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resistance without excessive weight gain in Zucker diabetic fatty rats[J]. Mol Cell Endocrinol, 2017, 439: 105-115.
[10]Huang H, Hu M, Zhao R, et al. Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway[J]. Oncol Rep, 2013, 30(5): 2467-2475.
[11]Huang X, Lian T, Guan X, et al. Dihydromyricetin reduces TGF-β via P53 activation- dependent mechanism in hepatocellular carcinoma HepG2 cells[J]. Protein Pept Lett, 2017, 24(5): 419-424.
[12]Tang N, Ma J, Ke SW, et al. Dihydromyricetin suppresses TNF-α-induced NF-κB activation and target gene expression[J]. Mol Cell Biochem, 2016, 422(1/2): 11-20.
[13]Wang R, Pi J, Su X, et al. Dihydromyricetin suppresses inflammatory responses in vitro and in vivo through inhibition of IKKβ activity in macrophages[J]. Scanning, 2016, 38(2): 119-124.
[14]Zhang W, Wang S, Yin H, et al. Dihydromyricetin enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells in vitro partially via the activation of Wnt/β-catenin signaling pathway[J]. Fundam Clin Pharmacol, 2016, 30(6): 596-606.
[15]Bostikova Z, Moserova M, Pavek P, et al. Role of dihydromyricetin in cytochrome P450-mediated metabolism and carcinogen activation[J]. Neuro Endocrinol Lett, 2015, 36(Suppl 1): 46-52.
[16]Hodek P, Fousova P, Brabencova E, et al. Effect of dihydromyricetin on benzo[a] pyrene activation in rats[J]. Neuro Endocrinol Lett, 2014, 35(Suppl 2): 158-168.
[17]Liang J, Shen Y, Shao XM, et al. Dihydromyricetin prevents fetal alcohol exposure-induced behavioral and physiological deficits: the roles of GABAA receptors in adolescence[J]. Neurochem Res, 2014, 39(6): 1147-1161.
[18]Wu B, Jie L, Jian L, et al. Dihydromyricetin protects against diabetic cardiomyopathy in streptozotocin-induced diabetic mice[J]. Biomed Res Int, 2017, 2017(1): 1-13. [19]Eger M, Sterer N, Liron T, et al. Scaling of titanium implants entrains inflammation-induced osteolysis[J]. Sci Rep, 2017, 1(7): 39612.
[20]Ping Z, Hu X, Wang L, et al. Melatonin attenuates titanium particle-induced osteolysis via activation of Wnt/β-catenin signaling pathway [J]. Acta Biomater, 2017, 10(51): 513-525.
[21]Zeng X, Zhang Y, Wang S, et al. Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca-NFATc1 signaling pathway and prevents ovariectomy-induced bone loss[J]. Biochem Pharmacol, 2017, 124: 57-68.
[22]Zhu L, Kang H, Guo CA, et al. Rifampin suppresses osteoclastogenesis and titanium particle-induced osteolysis via modulating RANKL signaling pathways[J]. Biochem Biophys Res Commun, 2017, 484(1): 64-70.
[23]Takada R, Jinno T, Koga D, et al. Comparison of wear rate and osteolysis between second-generation annealed and first-generation remelted highly cross-linked polyethylene in total hip arthroplasty. A case control study at a minimum of five years[J]. Orthop Traumatol Surg Res, 2017, 103(4): 537-541.
[24]Thienpont E. Titanium niobium nitride knee implants are not inferior to chrome cobalt components for primary total knee arthroplasty[J]. Arch Orthop Trauma Surg, 2015, 135(12): 1749-1754.
[25]Dalling JG, Math K, Scuderi GR. Evaluating the progression of osteolysis after total knee arthroplasty[J]. J Am Acad Orthop Surg, 2015, 23(3): 173-180.
[26]Ji FJ, Tian XF, Liu XW, et al. Dihydromyricetin induces cell apoptosis via a p53-related pathway in AGS human gastric cancer cells[J]. Genet Mol Res, 2015, 14(4): 15564-15571.
[27]Liu S, Ai Q, Kai F, et al. The cardioprotective effect of dihydromyricetin prevents ischemia-reperfusion-induced apoptosis in vivo and in vitro via the PI3K/Akt and HIF-1α signaling pathways[J]. Apoptosis, 2016, 21(12): 1366-1385.
[28]Wang Z, Sun X, Feng Y, et al. Dihydromyricetin reverses MRP2-mediated MDR and enhances anticancer activity induced by oxaliplatin in colorectal cancer cells[J]. Anti-cancer Drugs, 2017, 28(3): 281-288.
[29]侯小龙, 王文清, 施春阳, 等. 二氢杨梅素药理作用研究进展[J]. 中草药, 2015, 46(4): 603-609.
[30]Liu L, Yin X, Wang X, et al. Determination of dihydromyricetin in rat plasma by LC-MS/MS and its application to a pharmacokinetic study[J]. Pharm Biol, 2017, 55(1): 657-662.
[31]Liu P, Zou D, Chen K, et al. Dihydromyricetin improves hypobaric hypoxia-induced memory impairment via modulation of SIRT3 signaling[J]. Mol Neurobiol, 2016, 53(10): 7200-7212. |